NCT06910098

Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 195 (actual)
• Sponsor: Central Park Medical College · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: Accepted

Summary

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Conditions

• LDL - Low Density Lipoprotein Receptor Disorder
• Rosuvastatin

Interventions

Type	Name	Description
DRUG	Rosuvastatin	a dose of 5mg were given and were compared for the cpk, ast and ldl levels
DRUG	Rosuvastatin	a dose of 10 mg were given and were compared for the cpk, ast and ldl levels
DRUG	Rosuvastatin	a dose of 20 mg were given and were compared for the cpk, ast and ldl levels

Timeline

• Start date: 2023-12-01
• Primary completion: 2024-06-30
• Completion: 2024-08-31
• First posted: 2025-04-04
• Last updated: 2025-04-04

Locations

1 site across 1 country: Pakistan